Shire has signed a $70 million agreement with UCB to acquire the worldwide rights to Equasym IR and XL (methylphenidate hydrochloride), excluding the U.S., Canada and Barbados, for the treatment of ADHD. Equasym XL is approved and marketed in 10 countries and Equasym IR is marketed in four countries. In 2008 the products generated sales of $21.3 million in these territories. This acquisition adds to Shire’s ADHD portfolio and provides access to the European ADHD market as well as the op...